Gufic BioSciences Ltd
GUFICBIO NSE
Gufic BioSciences Ltd
HealthcareNSE: GUFICBIO BSE: 509079 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹4,132 Cr
Volatility
Moderate
P/E Ratio
56.07
EBITDA
₹154 Cr
Return on Equity
9.66%
Debt to Equity
0.61
Book Value
₹66.31
EPS
₹8.59
52W High
₹448
52W Low
₹268
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Gufic BioSciences Ltd insights
49 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
3- Stock is trading at 6.31 times its book value
- Company has a low return on equity of 13.5% over last 3 years.
- Dividend payout has been low at 1.40% of profits over last 3 years
Growth Rate
Revenue Growth
14.97% ↗
Net Income Growth
-7.76% ↘
Cash Flow Change
-63.17% ↘
ROE
-16.65% ↘
ROCE
-1.58% ↘
EBITDA Margin (Avg.)
-4.12% ↘
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 227 | 230 | 231 | 252 | 261 |
| Expenses | 160 | 176 | 165 | 161 | 167 | 166 | 174 | 178 | 195 | 195 | 195 | 206 | 214 |
| Operating Profit | 35 | 39 | 36 | 34 | 36 | 39 | 34 | 27 | 32 | 36 | 36 | 46 | 47 |
| OPM % | 18% | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 14% | 16% | 16% | 18% | 18% |
| Other Income | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 1 | -1 | 0 |
| Interest | 4 | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 | 8 | 9 | 9 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 | 8 | 8 | 8 |
| PBT | 28 | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 16 | 21 | 21 | 28 | 30 |
| Tax % | 26% | 25% | 25% | 26% | 26% | 26% | 26% | 26% | 26% | 27% | 26% | 26% | 26% |
| Net Profit | 21 | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 12 | 15 | 16 | 21 | 22 |
| EPS in Rs | 2.13 | 2.39 | 2.22 | 2 | 2.08 | 2.17 | 1.93 | 0.79 | 1.2 | 1.49 | 1.55 | 2.05 | 2.24 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 148 | 201 | 245 | 306 | 351 | 379 | 488 | 779 | 691 | 807 | 820 | 940 | 974 |
| Expenses | 134 | 181 | 222 | 267 | 305 | 327 | 404 | 631 | 556 | 657 | 683 | 790 | 810 |
| Operating Profit | 14 | 20 | 23 | 39 | 46 | 52 | 84 | 148 | 135 | 150 | 136 | 150 | 165 |
| OPM % | 10% | 10% | 9% | 13% | 13% | 14% | 17% | 19% | 20% | 19% | 17% | 16% | 17% |
| Other Income | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 3 | 3 | 0 | 4 | 3 | 2 |
| Interest | 4 | 6 | 6 | 9 | 10 | 14 | 14 | 5 | 8 | 17 | 25 | 37 | 37 |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 14 | 16 | 19 | 22 | 17 | 21 | 31 | 31 |
| PBT | 7 | 10 | 14 | 30 | 35 | 30 | 58 | 127 | 107 | 116 | 94 | 85 | 99 |
| Tax % | 36% | 29% | 37% | 45% | 38% | 25% | 23% | 24% | 25% | 26% | 26% | 26% | — |
| Net Profit | 4 | 7 | 9 | 16 | 22 | 23 | 44 | 96 | 80 | 86 | 70 | 63 | 74 |
| EPS in Rs | 0.54 | 0.95 | 1.17 | 2.13 | 2.82 | 2.92 | 5.68 | 9.89 | 8.22 | 8.59 | 6.97 | 6.3 | 7.33 |
| Div. Payout % | 9% | 5% | 4% | 2% | 2% | 2% | 2% | 1% | 1% | 1% | 1% | 2% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 19 | 26 | 30 | 46 | 68 | 120 | 164 | 259 | 338 | 523 | 591 | 654 |
| Borrowings | 33 | 43 | 57 | 80 | 98 | 126 | 62 | 64 | 334 | 333 | 336 | 405 |
| Other Liabilities | 67 | 75 | 84 | 104 | 106 | 152 | 157 | 188 | 179 | 227 | 232 | 273 |
| Total Liabilities | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 | 1,342 |
| Fixed Assets | 25 | 22 | 22 | 23 | 24 | 83 | 100 | 115 | 160 | 159 | 506 | 491 |
| CWIP | 0 | 0 | 0 | 2 | 10 | 31 | 13 | 41 | 170 | 307 | 22 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 3 |
| Other Assets | 102 | 130 | 156 | 213 | 245 | 294 | 279 | 365 | 531 | 625 | 639 | 826 |
| Total Assets | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 | 1,342 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 11 | -4 | -4 | -5 | 5 | 47 | 87 | 106 | -27 | -7 | 123 | 44 |
| Investing | -2 | -1 | -5 | -9 | -13 | -43 | -7 | -95 | -191 | -102 | -72 | -31 |
| Financing | -5 | 5 | 7 | 14 | 8 | -4 | -79 | -6 | 234 | 82 | -37 | 32 |
| Net Cash Flow | 4 | 0 | -1 | 1 | 0 | 0 | 2 | 5 | 17 | -27 | 14 | 45 |
| Free Cash Flow | 9 | -5 | -8 | -13 | -8 | 7 | 75 | 19 | -214 | -116 | 52 | 13 |
| CFO/OP | 92 | -8 | 2 | 30 | 33 | 110 | 115 | 94 | 1 | 13 | 107 | 37 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82 | 102 | 78 | 97 | 107 | 103 | 93 | 71 | 109 | 149 | 140 | 115 |
| Inventory Days | 165 | 180 | 190 | 238 | 190 | 249 | 138 | 102 | 202 | 188 | 211 | 281 |
| Days Payable | 223 | 188 | 132 | 192 | 157 | 238 | 162 | 125 | 143 | 156 | 155 | 173 |
| Cash Conversion Cycle | 25 | 94 | 136 | 143 | 141 | 114 | 69 | 48 | 167 | 181 | 197 | 224 |
| Working Capital Days | 4 | 18 | 14 | 26 | 40 | 17 | 63 | 50 | 68 | 97 | 93 | 81 |
| ROCE % | 18% | 24% | 24% | 33% | 30% | 21% | 29% | 46% | 23% | 17% | 13% | 12% |
Documents
1
Update On Further Investment In Selvax Pty Ltd.
29 Apr - Gufic invested USD 50,000 in Selvax Pty Ltd on April 28, 2026, acquiring 378,350 shares. 29 Apr - Gufic invested USD 50,000 in Selvax Pty Ltd on April 28, 2026, acquiring 378,350 shares.
2
Update On Further Investment In Selvax Pty Ltd.
29 Apr - Gufic invested USD 50,000 in Selvax Pty Ltd on April 28, 2026, acquiring 378,350 shares. 29 Apr - Gufic invested USD 50,000 in Selvax Pty Ltd on April 28, 2026, acquiring 378,350 shares.
3
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Apr - Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of physical shares is attached herewith 15 Apr - Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of physical shares is attached herewith
4
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Filed Regulation 74(5) compliance certificate for quarter ended March 31, 2026; no shareholder requests received. 7 Apr - Filed Regulation 74(5) compliance certificate for quarter ended March 31, 2026; no shareholder requests received.
5
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
3 Apr - Income tax appeal cuts demand to Rs 11.76 lakh; Rs 23.52 lakh penalty levied for AY2023-24. 3 Apr - Income tax appeal cuts demand to Rs 11.76 lakh; Rs 23.52 lakh penalty levied for AY2023-24.
Frequently Asked Questions about Gufic BioSciences Ltd
What does Gufic BioSciences Ltd do?
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
Where is Gufic BioSciences Ltd (GUFICBIO) listed?
Gufic BioSciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: GUFICBIO and BSE: 509079. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Gufic BioSciences Ltd belong to?
Gufic BioSciences Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Gufic BioSciences Ltd?
Gufic BioSciences Ltd has a market capitalisation of approximately ₹4131.64 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Gufic BioSciences Ltd?
The Price-to-Earnings (PE) ratio of Gufic BioSciences Ltd is 56.07. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Gufic BioSciences Ltd?
Over the past 52 weeks, Gufic BioSciences Ltd has traded between a low of ₹268 and a high of ₹448. This range helps investors understand the stock's price volatility and recent trading levels.
Does Gufic BioSciences Ltd pay dividends?
Yes, Gufic BioSciences Ltd has a dividend yield of 0.02%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Gufic BioSciences Ltd?
Gufic BioSciences Ltd has a Return on Equity (ROE) of 9.66%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Gufic BioSciences Ltd on Tapetide?
On Tapetide, you can view Gufic BioSciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
Website gufic.com
CEO Mr. Jayesh Pannalal Choksi
Employees 1,484
Listed 2004-10-19
Face Value ₹ 1
Issued Size 10,02,82,506